NEW YORK, December 24, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Verve Therapeutics, Inc. (“Verve” or the “Company”) VERV. Those investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, extension 7980.

The investigation concerns whether Verve and certain of its officers and/or directors have engaged in securities fraud or other illegal business practices.

[Click here for information about joining the class action]

On October 31, 2022, Verve issued a press release announc[ing] that preclinical data supporting VERVE-101 for the treatment of heterozygous familial hypercholesterolemia (HeFH), a genetic form of atherosclerotic cardiovascular disease (ASCVD), was published in the journal of the American Heart Association Traffic.” According to preclinical data reported by the company, VERVE-101 did not demonstrate significantly greater efficacy than statins, the traditional treatment for patients with high cholesterol.

As a result of this news, Verve’s stock price fell $3.00 per share, or 7.37%, to close at $37.70 per share on October 31, 2022.

Then, on November 7, 2022, Verve announced that “The U.S. Food and Drug Administration (FDA) stayed its IND application to conduct a clinical trial evaluating VERVE-101 in patients with heterozygous familial hypercholesterolemia (HeFH). has… in the United States.”

As a result of this news, Verve’s stock price fell $9.54 per share, or 30.49%, to close at $21.75 per share on November 7, 2022.

Then, on December 5, 2022, Verve announced that the FDA had requested additional data to resolve the clinical lockdown.

As a result of this news, Verve’s stock price fell $2.58 per share, or 10.75%, to close at $21.42 per share on December 5, 2022.

The Pomerantz law firm, with offices in New York, Chicago, Los Angeles and Paris, is one of the leading law firms in the areas of corporate, securities and antitrust litigation. Founded by the late…